Nivalis Therapeutics' IPO

Nivalis Therapeutics raised a round of funding on June 17, 2015. Investors include Public.

Nivalis Therapeutics, formerly N30Pharma, is developing a novel class of disease modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule wit…

Articles about Nivalis Therapeutics' IPO: